EGRX Eagle Pharmaceuticals
- 4.340
- -0.070-1.59%
Eagle Pharmaceuticals News
Eagle Pharmaceuticals Announces A Trial In Progress Presentation Of Phase 2/3 Study Of Intravenous Amisulpride As Prevention Of Postoperative Nausea And Vomiting In Pediatric Patients At The Upcoming Society For Ambulatory Anesthesia 2024 Annual Meeting
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company") today announced that it will deliver a Trial in Progress presentation discussing the ongoing Phase 2/3 study of intravenous amisulp
Sector Update: Health Care Stocks Softer Late Afternoon
Health care stocks eased late Monday afternoon, with the NYSE Health Care Index decreasing 0.1% and the Health Care Select Sector SPDR Fund (XLV) down 0.2%. The iShares Biotechnology ETF (IBB) fell 1.
Eagle Pharmaceuticals Says Phase 3 Data Show Amisulpride's Sustained Antiemetic Effect; Shares Rise
Eagle Pharmaceuticals (EGRX) shares climbed 9% in recent trading after the company said Monday that it will present phase III trial data showing that intravenous amisulpride may sustain an antiemetic
Express News | Eagle Pharmaceuticals To Present Additional Data From Phase 3 Trial Showing Sustained Response of Amisulpride For Rescue Treatment of Postoperative Nausea and Vomiting At Upcoming ASPAN 2024 National Conference
HROW, HCAT and EGRX Are Among After Hour Movers
Eagle Pharmaceuticals Risks Nasdaq Delisting Over Filing Delays
Express News | Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency From Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-K
Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency From Nasdaq Regarding Requirement to Timely File Annual Report On Form 10-K
Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency From Nasdaq Regarding Requirement to Timely File Annual Report On Form 10-K.
Sector Update: Health Care
Health care stocks fell late Monday afternoon with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) both easing 0.1%, paring earlier losses. The iShares Biotechnology ETF (
Eagle Pharmaceuticals CFO Resigns; Shares Fall
Eagle Pharmaceuticals (EGRX) shares fell 6% in recent Monday trading after Brian Cahill resigned as chief financial officer on Friday, effective immediately. The company said in a regulatory filing th
Eagle Pharmaceuticals Announces CFO Transition and Leadership Changes
Eagle Pharmaceuticals Announces Workforce Reduction
Eagle Pharmaceuticals Faces Nasdaq Delisting Deadline
Eagle Pharmaceuticals Updates Bendamustine IP Portfolio
Express News | Eagle Pharmaceuticals Provides Update on Bendamustine Intellectual Property Portfolio
Lifshitz Law PLLC Announces Investigations of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX), ON...
Eagle Pharmaceuticals To Present Abstract On Post-Hoc Analysis Of Amisulpride At The 77th PGA In New York City
-- BARHEMSYS (amisulpride) Injection is the first and only antiemetic approved by the U.S. Food and Drug Administration ("FDA") for rescue treatment of postoperative nausea and vomiting ("PONV") despi
Eagle Pharmaceuticals, Inc. (EGRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages...
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersAltimmune (NASDAQ:ALT) shares increased by 45.2% to $4.59 during Thursday's after-market session. The company's market cap stands at $246.6 million. NovaBay Pharmaceuticals (AMEX:NBY) stock inc
Sector Update: Health Care Stocks Mixed Late Afternoon
Health care stocks were mixed late Wednesday afternoon with the NYSE Health Care Index slightly higher and the Health Care Select Sector SPDR Fund (XLV) fractionally lower. The iShares Biotechnology E
Analysis
Price Target
No Data
